These agents can block the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 or the programmed death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1), leading to T-cell mediated tumor cell destruction. The gene discussed is CD274; the disease is neoplasm.